BNP Paribas Exane analyst Peter Verdult initiated coverage of Novartis (NVS) with an Outperform rating and $116 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke
- Novartis Stock (NVS) Looks Healthier as it Spends $23B on Ramping Up U.S. Manufacturing
- Novartis announces planned $23B investment over five years in U.S.
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Travere Therapeutics price target lowered to $27 from $31 at BofA